Paranovus Entertainment Technology Ltd.
NASDAQ:PAVSMedical - Pharmaceuticals
+$1.28 today
- Market cap
- $353.07M
- Beta
- -0.35
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$9.07
Volume 0.16M
Average 113.44M
PAVS Income Before Tax
Profit after all operating and non-operating items but before income tax.
Paranovus Entertainment Technology Ltd.NASDAQ: PAVS
Income Before Tax · Q2 FY2025 · quarter ended Sep 2025
Income before tax remains negative
Q2 FY2025 income before tax was -$583.24K, compared with -$1.29M a year earlier.
Context
- Income before tax amounted to 9788.2% of revenue in FY2024.
- Income before tax grew in size in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Before Tax history
USD · from the income statement
- Latest · FY2024
- (7M) USD
- Year-over-year change
- -63.3%
| Period | Period end | Income Before Tax | YoY change |
|---|---|---|---|
| FY2024 | 2025-03-31 | (7M) | -63.3% |
| FY2023 | 2024-03-31 | (4.29M) | +5.3% |
| FY2022 | 2023-03-31 | (4.53M) | +92.2% |
| FY2021 | 2022-03-31 | (57.75M) | -3596.9% |
| FY2020 | 2021-03-31 | 1.65M | — |
Income Before Tax vs competitors
How PAVS compares with its peers on the latest reported figures
- PAVS's FY2024 income before tax of -$7M is the lowest of the 4 companies compared; the peer median is -$6.06M.
- Its year-over-year change of -63.3% is the 3rd highest of 4, against a peer median of -51.5%.
- Income before tax amounts to 9788.2% of revenue for PAVS, versus a peer median of 14.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
WYHGWing Yip Food Holdings Group Limited American Depositary Shares | LTM Mar 2026 | $6.81M | -25.9% | -15.7% | 5.2% |
| LTM Mar 2026 | -$6.06M | -554.8% | — | 14.3% | |
| LTM Mar 2026 | -$7M | -51.5% | — | 53.3% | |
| FY2024 | -$7M | -63.3% | — | 9788.2% | |
| Peer median (excluding PAVS) | -$6.06M | -51.5% | -15.7% | 14.3% | |
Competitors are the stored peer set for PAVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2020 Mar 2021 | FY2021 Mar 2022 | FY2022 Mar 2023 | FY2023 Mar 2024 | FY2024 Mar 2025 |
|---|---|---|---|---|---|
| Revenue | 71.48M | 89.49M | 23.33M | 0 | 71.54K |
| Cost of Revenue | 53.31M | 85.78M | 22.92M | 380K | 442.53K |
| Gross Profit | 18.18M | 3.71M | 416.88K | (380K) | (370.98K) |
| Gross Margin | 25.4% | 4.1% | 1.8% | — | -518.6% |
| Research & Development | 1.66M | 1.68M | 1.4M | 0 | 0 |
| Selling, General & Admin | 14.99M | 49.6M | 4.97M | 2.08M | 1.93M |
| Operating Expenses | 16.65M | 51.29M | 4.97M | 2.08M | 1.93M |
| Depreciation & Amortization | 880.88K | 2.19M | 58.75K | 380K | 380K |
| EBITDA | 2.41M | (45.39M) | (4.49M) | (2.08M) | (1.92M) |
| EBITDA Margin | 3.4% | -50.7% | -19.2% | — | -2682.4% |
| Operating Income | 1.53M | (47.58M) | (4.55M) | (2.46M) | (2.3M) |
| Operating Margin | 2.1% | -53.2% | -19.5% | — | -3213.6% |
| Interest Income | 131.9K | 108.4K | 316 | 0 | 156 |
| Interest Expense | 111.8K | 85.99K | 72.3K | 39.17K | 261.85K |
| Other Income / Expenses | 125.62K | (10.17M) | 22.04K | (1.83M) | (4.7M) |
| Income Before Tax | 1.65M | (57.75M) | (4.53M) | (4.29M) | (7M) |
| Pre-Tax Margin | 2.3% | -64.5% | -19.4% | — | -9788.2% |
| Income Tax Expense | 959.38K | (3.73M) | 3K | 0 | 0 |
| Net Income | 786.36K | (49.19M) | (71.74M) | (17.67M) | (7.53M) |
| Net Margin | 1.1% | -55.0% | -307.5% | — | -10519.7% |
| EPS (Basic) | 72.14 | (2,916.00) | (1,516.10) | (448.12) | (10.69) |
| EPS (Diluted) | 72.14 | (2,916.00) | (1,516.10) | (448.12) | (10.69) |
| Weighted Avg Shares | 10.9K | 16.86K | 47.31K | 39.43K | 704.27K |
| Weighted Avg Shares (Diluted) | 10.9K | 16.86K | 47.31K | 39.43K | 704.27K |
Paranovus Entertainment Technology Ltd.
NASDAQ:PAVS
Intrinsic Alpha fair value
Locked
Current Price
$7.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.